Addendum: ENTA’s Mavyret/Glecaprevir royalties from ABBV will be in the 17% tier for almost all of the Jul-Sep 2018 sales and for all of the Oct-Dec 2018 sales.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”